Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
Home / Complement 3 Glomerulopathy
Browsing Tag: Complement 3 Glomerulopathy
Social Icons
Featured Posts
1
AbbVie’s Boey Approved in Canada for Glabellar Lines
June 24, 20262
Roche’s Itovebi Moves Closer to Public Access in Canada
June 24, 20263
